Diagnosis and management of genetic haemochromatosis

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 2, 2002, Pages 277-293

  Dooley, James S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cirrhosis; Diabetes mellitus; Genetic haemochromatosis; Hepatocellular carcinoma; Liver biopsy; Serum ferritin; Transferrin saturation; Venesection

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTIARRHYTHMIC AGENT; ASCORBIC ACID; BILIRUBIN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYCLOOXYGENASE 2 INHIBITOR; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; FERRITIN; FOLLITROPIN; GAMMA GLUTAMYLTRANSFERASE; GLYCOSYLATED HEMOGLOBIN; INSULIN; IRON; IRON CHELATING AGENT; LUTEINIZING HORMONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; ORAL ANTIDIABETIC AGENT; SEX HORMONE; TESTOSTERONE; THYROTROPIN; THYROXINE; TRANSFERRIN; UNINDEXED DRUG; ALPHA FETOPROTEIN; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HFE PROTEIN;

ARTHRALGIA; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; EARLY DIAGNOSIS; EARLY MENOPAUSE; FEMALE; FERRITIN BLOOD LEVEL; GENE MUTATION; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; HEART DISEASE; HEMOCHROMATOSIS; HOMOZYGOSITY; HUMAN; IRON DEFICIENCY; IRON OVERLOAD; LIBIDO DISORDER; LIFE EXPECTANCY; LIVER BIOPSY; LIVER DISEASE; MALE; MUTATIONAL ANALYSIS; OSTEOPOROSIS; PATIENT CARE; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THYROID DISEASE; AMENORRHEA; AMINOTRANSFERASE BLOOD LEVEL; ARTHRITIS; BONE DENSITOMETRY; CARDIOMYOPATHY; CHELATION THERAPY; CHRONIC LIVER DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHY; ECHOGRAPHY; ELECTROCARDIOGRAM; FAMILY HISTORY; GENETIC HEMOCHROMATOSIS; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEART ARRHYTHMIA; HEMOGLOBIN DETERMINATION; HORMONE SUBSTITUTION; HYPOPITUITARISM; IMPOTENCE; INFERTILITY; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON INTAKE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; MASS SCREENING; POLYMERASE CHAIN REACTION; PROTHROMBIN TIME; RADIOGRAPHY; SKIN PIGMENTATION; TRANSFERRIN BLOOD LEVEL; ALGORITHM; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DISEASE MANAGEMENT; GENETICS;

ALGORITHMS; DISEASE MANAGEMENT; HEMOCHROMATOSIS; HUMANS; IRON OVERLOAD; LABORATORY TECHNIQUES AND PROCEDURES; PHLEBOTOMY;

EID: 0036431558     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(02)90006-X     Document Type: Review

References (59)

1. Camaschella C. Juvenile haemochromatosis. Baillière's Clinical Gastroenterology 1998; 12: 227-235.
2. Roetto A, Totaro A, Cazzola M et al. Juvenile hemochromatosis locus maps to chromosome 1q. American Journal of Human Genetics 1999; 64: 1388-1393.
3. Brandhagen DJ, Alvarez W, Therneau TM et al. Iron overload in cirrhosis - HFE genotypes and outcome after liver transplantation. Hepatology 2000; 31: 456-460.
4. Mendler MH, Turlin B, Moirand R et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-1163.
5. Jackson HA, Carter K, Darke C et al. HFE mutations, iron deficiency and overload in 10 500 blood donors. British Journal of Haematology 2001; 114: 474-484.
6. Beutler E, Felitti VJ, Koziol JA et al. Penetrance of 845G-A(C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211-218.
7. Edwards CQ & Kushner JP. Screening for hemochromatosis. New England Journal of Medicine 1993; 328: 1616-1620.
8. International Committee for Standardisation in Haematology. The measurement of total and unsaturated iron binding capacity in serum. British Journal of Haematology 1978; 38: 281-290.
9. National Committee for Clinical Laboratory Standards (NCCLS). Determination of serum iron and total iron-binding capacity: proposed standard H17-P. Villanova, PA: NCCLS, 1990.
10. Vernet M & LeGall JY. Transferrin saturation and screening of genetic haemochromatosis. Clinical Chemistry 1998; 44: 360-361.
11. Adams PC, Gregor JC, Kertesz AE & Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterology 1995; 109: 177-188.
12. Hickman PE, Hourigan LF, Powell LW et al. Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous haemochromatosis. Gut 2000; 46: 405-409.
13. Lee MH & Means RT. Extremely elevated serum ferritin levels in a University Hospital: associated diseases and clinical significance. American Journal of Medicine 1995; 98: 566-571.
14. Bacon BR, Farahvash MJ, Janney CG & Neuschwander-Tetri BA. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-1109.
15. Feder JN, Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nature Genetics 1996; 13: 399-408.
16. Jeffrey GP, Chakrabarti S, Hegele RA & Adams PC. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nature Genetics 1999; 22: 325-326.
17. Merryweather-Clarke AT, Pointon JJ, Shearman JD et al. Polymorphism in intron 4 of HFE does not compromise haemochromatosis mutation results. Nature Genetics 1999; 23: 271-272.
18. The UK Haemochromatosis Consortium. A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut 1997; 41: 841-844.
19. Bacon BR, Powell LW, Adams PC et al. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999; 116: 193-207.
20. Wallace DF, Walker AP, Pietrangelo A et al. Frequency of the S65C mutation of HFE and iron overload in 309 subjects heterozygous for C282Y. Journal of Hepatology 2002; 36: 474-479.
21. Bassett ML, Halliday JW & Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986; 6: 24-29.
22. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. Journal of Hepatology 2001; 35: 421-430.
23. George DK, Ramm GA, Walker NI et al. Elevated serum type IV collagen: a sensitive indicator for the presence of cirrhosis in haemochromatosis. Journal of Hepatology 1999; 31: 47-52.
24. Guyader D, Jacquelinet C, Moirand R et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998; 115: 929-936.
25. British Committee for Standards in Haematology. Guidelines on diagnosis and treatment. Genetic Haemochromatosis. www.bcshguidelines.com/ (see under Haemato Oncology) 2000; 13-14.
26. Bacon BR, Olynyk JK, Brunt EM et al. HFE genotype in patients with hemochromatosis and other liver diseases. Annals of Internal Medicine 1999; 130: 953-962.
27. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001; 33: 1321-1328.
28. Guyader D & Gandon Y. Computed tomography and magnetic resonance imaging in the diagnosis of hemochromatosis. In Barton JC & Edwards CO (eds) Hemochromatosis: genetics, pathophysiology, diagnoses and treatment pp 219-225. Cambridge: Cambridge University Press, 2000.
29. Piperno A, Sampietro M, Pietrangelo A et al. Heterogeneity of hemochromatosis in Italy. Gastroenterology 1998; 114: 996-1002.
30. Mertz JF, Kriss AG, Leonard DGB & Cho MK. Diagnostic testing fails the test. Nature 2002; 415: 577-579.
31. Distante S, Berg JP, Lande K et al. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis. Gut 2000; 47: 575-579.
32. Camaschella C, Roetto A, Cali A et al. The gene TRF2 is mutated in a new type of haemochromatosis mapping to 7q22. Nature Genetics 2000; 25: 14-15.
33. Roetto A, Totaro A, Piperno A et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001; 917: 2555-2560.
34. Kato J, Fujikawa K, Kanda M et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. American Journal of Human Genetics 2001; 69: 191-197.
35. Montosi G, Donovan A, Totaro A et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLCIIA3) gene. Journal of Clinical Investigation 200 1; 108: 619-623.
36. Njajou OT, Vaessen N, Joosse M et al. A mutation in SLCIIA3 is associated with autosomal dominant hemochromatosis. Nature Genetics 2001; 28: 213-214.
37. Devalia V, Carter K, Walker AP et al. Autosomal dominant reticulo-endothelial iron overload associated with a three base pair deletion in the ferroportin I gene (SLCIIA3). Blood 2002; 100: 715-717.
38. Adams P, Brissot P & Powell LW. EASL International Consensus Conference on Haemochromatosis. Journal of Hepatology 2000; 33: 485-504.
39. Merryweather-Clark AT, Pointon JJ, Jouanolle AM et al. Geography of HFE C282Y and H63D mutations. Genetic Testing 2000; 4: 183-198.
40. Yang Q, McDonnell SM, Khoury MJ et al. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data. Annals of Internal Medicine 1998; 129: 946-953.
41. Merryweather-Clarke AT, Worwood M, Parkinson L et al. The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. British Journal of Haematology 101; 369-373.
42. Adams PC, Kertesz AE, McLaren C et al. Population screening for hemochromatosis: a comparison of unbound iron binding capacity, transferrin saturation and C282Y genotyping in 5,211 voluntary blood donors. Hepatology 1999; 30: 502A (Abstract).
43. Phatak PD, Sham RL, Raubertas RF et al. Prevalence of hereditary hemochromatosis in 16,031 primary care patients. Annals of Internal Medicine 1998; 129: 954-961.
44. Powell LW. Does transplantation of the liver cure haemochromatosis. Journal of Hepatology 1992; 16: 259-261.
45. Risch N. Haemochromatosis, HFE and genetic complexity. Nature Genetics 1997; 17: 375-376.
46. Adams PC. Implications of genotyping of spouses to limit investigation in children in genetic haemochromatosis. Clinical Genetics 1998; 53: 176-178.
47. Edwards CQ, Kelly TM, Ellwein G & Kushner JP. Thyroid disease in hemochromatosis. Increased incidence in homozygous men. Archives of Internal Medicine 1983; 143: 1890-1893.
48. Niederau C, Fischer R, Purschel A et al. Survival in patients with hemochromatosis. New England Journal of Medicine 1996; 110: 1107-1119.
49. Powell LW. Hemochromatosis: the impact of early diagnosis and therapy. Gastroenterology 1996; 110: 1304-1307.
50. De Gobbi M, Pasquero P, Brunello F et al. Juvenile hemochromatosis associated with β-thalassemia treated by phlebotomy and recombinant human erythropoietin. Haematologica 2000; 85: 865-867.
51. Niederau C, Fischer R, Sonnenberg A et al. Survival and causes of death in cirrhotic and in non-cirrhotic patients with hemochromatosis. New England Journal of Medicine 1985; 313: 1256-1262.
52. Fargion S, Fracanzani AL, Piperno A et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994; 20: 1426-1431.
53. Farrell FJ, Nguyen M, Woodley S et al. Outcome of liver transplantation in patients with haemochromatosis. Hepatology 1994; 20: 404-410.
54. Brandhagen DJ. Liver transplantation for hereditary hemochromatosis. Liver Transplantation 2001; 7: 663-672.
55. Cecchetti G, Binda A, Piperno A et al. Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: polygraphic and echocardiographic evaluation. European Heart Journal 1991; 12: 224-230.
56. Diamond T, Stiehl D & Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Annals of Internal Medicine 1989; 110: 430-436.
57. Eyres KS, McClasky EV, Fern ED et al. Osteoporotic fractures: an unusual presentation of haemochromatosis. Bone 1992; 13: 431-433.
58. Lindor KD, Jorgensen RA, Tiegs RD et al. Etidronate for osteoporosis in primary biliary cirrhosis: a randomised trial. Journal of Hepatology 2000; 33: 878-882.
59. Adams PC & Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Hepatology 1996; 23: 724-727.